Question 1

Am I eligible for this trial based on my current health and treatment history?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation clinical trial (NCT02074839). Contact the study team or your healthcare provider for specific answers.

Question 2

What are the potential side effects of AG-120?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation clinical trial (NCT02074839). Contact the study team or your healthcare provider for specific answers.

Question 3

How does AG-120 compare to my current treatment options?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation clinical trial (NCT02074839). Contact the study team or your healthcare provider for specific answers.

Question 4

What will the treatment schedule look like, and how often will I need to visit the clinic?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation clinical trial (NCT02074839). Contact the study team or your healthcare provider for specific answers.

Question 5

What tests will I need to undergo during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation clinical trial (NCT02074839). Contact the study team or your healthcare provider for specific answers.

Question 6

How long can I expect to be on this treatment?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation clinical trial (NCT02074839). Contact the study team or your healthcare provider for specific answers.

What this study is about